Wheeler, D C, Jongs, N, Stefansson, B, Chertow, G M, Greene, T, Hou, F F, Langkilde, A M, McMurray, J J, Rossing, P, Nowicki, M, Wittmann, I, Correa-Rotter, R, Sjostrom, C D, Toto, R D, Heerspink, H J L & DAPA-CKD Trial Comm Investigators 2022, ' Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis : a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial ', Nephrology Dialysis Transplantation, vol. 37, no. 9, pp. 1647–1656 . https://doi.org/10.1093/ndt/gfab335
JACC. Heart failure, 9(11), 807-820. ELSEVIER SCI LTD McMurray, J J V, Wheeler, D C, Stefánsson, B V, Jongs, N, Postmus, D, Correa-Rotter, R, Chertow, G M, Hou, F F, Rossing, P, Sjöström, C D, Solomon, S D, Toto, R D, Langkilde, A M, Heerspink, H J L & DAPA-CKD Trial Committees and Investigators 2021, ' Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure ', JACC: Heart Failure, vol. 9, no. 11, pp. 807-820 . https://doi.org/10.1016/j.jchf.2021.06.017
Journal of the American Society of Nephrology, 32(8), 2352-2361. AMER SOC NEPHROLOGY Chertow, G M, Vart, P, Jongs, N, Toto, R D, Gorriz, J L, Hou, F F, McMurray, J J V, Correa-Rotter, R, Rossing, P, Sjöström, C D, Stefánsson, B V, Langkilde, A M, Wheeler, D C & Heerspink, H J L 2021, ' Effects of dapagliflozin in stage 4 chronic kidney disease ', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2352-2361 . https://doi.org/10.1681/ASN.2021020167 J Am Soc Nephrol
Chertow, G M, Vart, P, Jongs, N, Langkilde, A M, McMurray, J J V, Correa-Rotter, R, Rossing, P, Sjöström, C D, Stefansson, B V, Toto, R D, Wheeler, D C & Heerspink, H J L 2022, ' Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease ', Diabetes, Obesity and Metabolism, vol. 24, no. 5, pp. 827-837 . https://doi.org/10.1111/dom.14641 Diabetes obesity & metabolism, 24(5). Wiley